First Report of KPC-2-Producing Klebsiella pneumoniae Strains in Brazil

The carbapenems are regarded as the preferential therapeu-tic option for treatment of serious health care-associated in-fections with multidrug-resistant gram-negative bacteria. Al-though carbapenem resistance is rarely described for the Enterobacteriaceae (6), this phenotype of resistance has been increasingly reported worldwide, especially due to the emer-gence and spread of Klebsiella pneumoniae carbapenemase (KPC) (1, 5, 8). In this report, we describe the first detection of KPC-2-producing K. pneumoniae strains in Brazil. These strains also coproduced an extended-spectrum -lactamase, CTX-M-2